bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel
Clicks: 227
ID: 212175
2011
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
3.6
/100
12 views
12 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m2 i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks. Results. Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated. Conclusion. Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.
| Reference Key |
francini2011prostatebevacizumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Filippo Francini;Alessandra Pascucci;Edoardo Francini;Gianluca Bargagli;Raffaele Conca;Antonella Licchetta;Giandomenico Roviello;Ignazio Martellucci;Giorgio Chiriacò;Salvatora Tindara Miano;Giuseppe Marzocca;Antonio Manganelli;Roberto Ponchietti;Vinno Savelli;Roberto Petrioli |
| Journal | seminars in radiation oncology |
| Year | 2011 |
| DOI |
10.1155/2011/258689
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.